Pancreatic Ductal Adenocarcinoma

Annually, around 90.000 people in Europe get diagnosed with pancreatic ductal adenocarcinoma (PDAC), commonly known as pancreatic cancer. The overall 12 months survival rate is around 20%, whereas the 5 year survival rate decreases to 4%. PDAC is one of the most severe types of cancer based on a poor early diagnosis, difficulties in surgical resection and a high resistance to radiation- or chemotherapy. Characteristic for PDAC is the highly dense tumor stroma (or microenvironment) consisting of pancreatic cancer cells, endothelial cells, immune cells, extra cellular matrix and a significantly high amount of cancer-associated fibroblasts (CAFs).